Contra-indicated in patients with active pathological bleeding or with a mechanical prosthetic heart valve.
- TRADE NAME: Pradaxa (Boehringer Ingelheim)
- INDICATIONS: Prevention of venous thromboembolic events, reduce stroke risk
- CLASS: Anticoagulant (antithrombotic), Thrombin inhibitor
- HALF-LIFE: 2.5 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Antacids, Anticoagulants, Atorvastatin, Carbamazepine, Clarithromycin, Clopidogrel, Collagenase, Cyclosporine, Daclatasvir, Darunavir, Dasatinib, Deferasirox, Desirudin, Dextran, Diclofenac, Dronedarone, Fondaparinux, Heparin, Ibritumomab, Itraconazole, Ketoconazole, Ketorolac, Lapatinib, Meloxicam, Nandrolone, Neratinib, NSAIDs, P-glycoprotein inducers and inhibitors, Pantoprazole, Pentosan, Phenytoin, Polysulfate sodium, Prostacyclin analogues, Proton pump inhibitors, Quinidine, Rifampin, Rivaroxaban, Salicylates, St John's Wort, Sulfinpyrazone, Tacrolimus, Telaprevir, Thrombolytic agents, Ticlopidine, Tipranavir, Tositumomab & Iodine131, Ulipristal, Verapamil, Vitamin K antagonists
- See adverse reactions attributed to class:
DISCONTINUING PRADAXA IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 02/17/2025
